肺癌市場規模、佔有率、成長分析、按診斷/治療、按適應症、按最終用途、按地區 - 行業預測，2024-2031 年

2022年全球肺癌市場規模為294.5億美元，從2023年的326.6億美元成長到2031年的747.3億美元，年複合成長率預計為10.9%。

全球肺癌市場是一個重要的醫療保健領域，專注於對公共衛生構成重大挑戰的流行和致命疾病的診斷、治療和管理。由於吸煙、環境污染物和遺傳因素導致發病率上升，標靶治療和免疫療法等診斷和治療方案的創新進步正在推動市場發展。從傳統化療到個人化和有效治療的顯著轉變改善了患者的治療效果，同時提高了對早期檢測和預防措施的認知正在推動市場成長。儘管存在治療成本和可及性等挑戰，但正在進行的研究與人工智慧和巨量資料的整合有望徹底改變診斷和治療策略，而這個不斷發展的市場顯示出患者照護改善和成長的巨大潛力。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2023）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析
• 技術分析
• 監管分析
• 專利分析
• 案例研究分析
• 管道分析

肺癌市場規模：依診斷/治療及年複合成長率（2024-2031）

• 市場概況
• 診斷
  • 支氣管鏡檢查
  • TTNA
  • 影像
  • 腫瘤生物標記檢測
  • 原位雜合技術
  • 其他
• 治療
  • 非侵入性
  • 免疫療法
  • 標靶治療
  • 微創
  • 射頻消融術
  • 微波消融
  • 熱凝固/冷凍療法

肺癌市場規模：依適應症及年複合成長率（2024-2031）

• 市場概況
• 非小型基地台肺癌
• 小型基地台肺癌

肺癌市場規模：依最終用途及年複合成長率（2024-2031）

• 市場概況
• 醫院
• 診斷實驗室
• 影像診斷中心
• 學術界
• 專科診所

肺癌市場規模及年複合成長率（2024-2031）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2023）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
  • 收益與前一年同期比較（2021-2023）

主要企業簡介

• F. Hoffmann-La Roche（Switzerland）
• AstraZeneca（UK）
• Sanofi（France）
• Pfizer, Inc.（US）
• Bristol-Myers Squibb Company（US）
• Sysmex Corporation（Japan）
• Thermo Fisher Scientific（US）
• Qiagen（Germany）
• Janssen Pharmaceuticals（US）
• Quest Diagnostics（US）
• Takeda Pharmaceutical Company（Japan）
• Novartis AG（Switzerland）
• Eli Lilly & Company（US）
• Merck & Co., Inc.（US）
• Boehringer Ingelheim（Germany）
• Merck KGaA（EMD Serono）（Germany）
• AbbVie（US）
• Astellas Pharma（Japan）
• GlaxoSmithKline（UK）
• Johnson & Johnson（US）

結論和建議

Global Lung Cancer Market size was valued at USD 29.45 billion in 2022 and is poised to grow from USD 32.66 billion in 2023 to USD 74.73 billion by 2031, growing at a CAGR of 10.9% during the forecast period (2024-2031).

The global lung cancer market represents a vital healthcare sector focused on diagnosing, treating, and managing a prevalent and lethal disease that poses significant public health challenges. With rising incidences primarily attributed to smoking, environmental pollutants, and genetic factors, the market is fueled by innovative advancements in diagnostic and therapeutic options, such as targeted therapies and immunotherapies. A notable shift from traditional chemotherapy to personalized and effective treatments enhances patient outcomes, while increased awareness of early detection and preventative measures drives market growth. Despite challenges like treatment costs and accessibility, ongoing research, alongside the integration of artificial intelligence and big data, promises to revolutionize diagnosis and therapeutic strategies, showcasing significant potential for improved patient care and growth within this evolving market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lung Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Lung Cancer Market Segmental Analysis

Global Lung Cancer Market is segmented by diagnostics, indication, end-use and region. Based on diagnostics, the market is segmented into diagnostics and therapy. Based on indication, the market is segmented into non-small cell lung cancer and small cell lung cancer. Based on end-use, the market is segmented into hospitals, diagnostic laboratories, diagnostic imaging centers, academia, specialty clinics, and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Lung Cancer Market

A significant catalyst for the global lung cancer market is the relentless progress in medical research and technology. The growing comprehension of lung cancer biology, alongside breakthroughs in diagnostic tools, targeted therapies, immunotherapies, and precision medicine, is propelling market growth. These innovations not only introduce novel treatment alternatives but also enhance patient outcomes and facilitate early detection. The shift towards personalized treatment strategies allows healthcare providers to tailor interventions to individual patient profiles, further driving the demand for advanced lung cancer therapies. Consequently, these technological advancements are pivotal in shaping the future landscape of the lung cancer treatment market.

Restraints in the Global Lung Cancer Market

One of the main challenges facing the global lung cancer market is the exorbitant cost associated with treatments. Patients often confront substantial financial burdens due to the high prices of lung cancer therapies, such as targeted treatments and immunotherapies. This issue can severely limit patient access to these advanced options, particularly in areas with limited healthcare resources or insufficient insurance coverage. Consequently, the overall affordability and accessibility of lung cancer treatments create significant obstacles that can impede the market's growth and hinder the provision of equitable care to patients, ultimately affecting the broader adoption of essential therapies.

Market Trends of the Global Lung Cancer Market

The global lung cancer market is witnessing a significant trend towards precision medicine and targeted therapies, driven by advancements in genomic research and molecular characterization of tumors. This shift fosters the development of personalized treatment regimens that specifically address genetic mutations and biomarkers unique to each patient. As healthcare systems prioritize improved treatment outcomes and reduced adverse effects, the demand for tailored therapies is surging. Furthermore, the integration of molecular profiling techniques is enhancing the efficacy of treatments, promising better patient care and prognosis. This evolution not only reshapes therapeutic approaches but also amplifies the potential for innovation in lung cancer management globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Study Analysis
• Pipeline Analysis

Global Lung Cancer Market Size by Diagnostics & Therapy & CAGR (2024-2031)

• Market Overview
• Diagnostics
  • Bronchoscopy
  • TTNA
  • Imaging
  • Tumor Biomarker Test
  • In Situ Hybridization
  • Others
• Therapy
  • Non-Invasive
  • Immunotherapy
  • Targeted Therapy
  • Minimally Invasive
  • Radiofrequency Ablation
  • Microwave Ablation
  • Thermal/Cryoablation

Global Lung Cancer Market Size by Indication & CAGR (2024-2031)

• Market Overview
• Non-Small Cell Lung Cancer
• Small Cell Lung Cancer

Global Lung Cancer Market Size by End-Use & CAGR (2024-2031)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Diagnostic Imaging Centers
• Academia
• Specialty Clinics

Global Lung Cancer Market Size & CAGR (2024-2031)

• North America (Diagnostics & Therapy, Indication, End-Use)
  • USA
  • Canada
• Europe (Diagnostics & Therapy, Indication, End-Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnostics & Therapy, Indication, End-Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnostics & Therapy, Indication, End-Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnostics & Therapy, Indication, End-Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• F. Hoffmann-La Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly & Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (EMD Serono) (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations